Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)



Status:Active, not recruiting
Conditions:Lung Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/4/2019
Start Date:December 3, 2015
End Date:July 29, 2019

Use our guide to learn which trials are right for you!

A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients With Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-based Chemotherapy

The main purpose of the 15743 study is to assess efficacy and safety of anetumab ravtansine
versus vinorelbine in progression free survival in patients with stage IV mesothelin
overexpressing malignant pleural mesothelioma (MPM).

210 eligible patients will be randomized to receive either anetumab ravtansine every three
weeks or weekly vinorelbine.

Treatment will continue until centrally confirmed disease progression or until another
criterion is met for withdrawal from the study. Patients will enter follow up phase to
capture safety and endpoint data as required.

Efficacy will be measured by evaluating progression free survival from randomization.
Radiological tumor assessments will be performed at defined time points until the patient's
disease progresses.

Blood samples will be collected for safety, pharmacokinetic and biomarker analysis. Archival
or fresh biopsy tissue may also be collected for central pathology review and biomarkers.


Inclusion Criteria:

- Histological documentation of malignant pleural mesothelioma (MPM) overexpressing
mesothelin

- Unresectable locally advanced or metastatic MPM after locally confirmed progression on
1st line treatment with platinum in combination with pemetrexed.

- Patients must have measurable disease

- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1

- Life expectancy of at least 3 months.

- Adequate bone marrow, liver and renal function

- Left ventricular ejection fraction (LVEF) ≥ 50% or the lower limit of normal (LLN)
according to local institution ranges of normality.

Exclusion Criteria:

- More than 1 previous systemic anti-cancer therapy line

- Patients with corneal epitheliopathy or any eye disorder that may predispose the
patients to this condition at the discretion of the investigator in consultation with
the ophthalmologist.

- Brain metastases, meningeal tumours or other metastases in the central nervous system

- Evidence of history of bleeding diathesis.

- Ongoing or active infection (bacterial, fungal, or viral) of National Cancer
Institute's Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03
Grade > 2.

- Pre-existing cardiac conditions
We found this trial at
16
sites
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Bethesda, MD
Click here to add this to my saved trials
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Durham, NC
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
La Jolla, CA
Click here to add this to my saved trials
?
mi
from
New Orleans, LA
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Norwich, CT
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
St Leonards, New South Wales 2065
?
mi
from
St Leonards,
Click here to add this to my saved trials
?
mi
from
Tampa, FL
Click here to add this to my saved trials